Home    Back

2. Amyotrophic lateral sclerosis
508 clinical trials,   530 drugs   (DrugBank: 146 drugs),   170 drug target genes,   221 drug target pathways

Searched query = "Amyotrophic lateral sclerosis", "ALS"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
8 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT04322149
(ClinicalTrials.gov)		October 16, 202020/3/2020Multiple Doses of AT-1501-A201 in Adults With ALSA Phase 2a Open-Label, Multi-Center Study to Evaluate the Safety and Tolerability of Multiple Doses of AT-1501 in Adults With ALSAmyotrophic Lateral SclerosisDrug: AT-1501Anelixis Therapeutics, Inc.NULLRecruiting18 YearsN/AAll54Phase 2United States
2NCT04066244
(ClinicalTrials.gov)		December 30, 201921/8/2019Study of Safety and of the Mechanism of BLZ945 in ALS PatientsAn Open-label, Adaptive Design Study in Patients With Amyotrophic Lateral Sclerosis (ALS) to Characterize Safety, Tolerability and Brain Microglia Response, as Measured by TSPO Binding, Following Multiple Doses of BLZ945 Using Positron Emission Tomography (PET) With the Radioligand [11C]-PBR28Amyotrophic Lateral SclerosisDrug: BLZ945Novartis PharmaceuticalsNULLRecruiting18 YearsN/AAll20Phase 2United States;Finland;Sweden
3EUCTR2019-000826-22-FI
(EUCTR)		05/11/201918/09/2019Study of safety and of the mechanism of BLZ945 in amyotrophic lateral sclerosis (ALS) patients.An open-label, adaptive design study in patients with amyotrophic lateral sclerosis (ALS) to characterize safety, tolerability and brain microglia response, as measured by TSPO binding, following multiple doses of BLZ945 using positron emission tomography (PET) with the radioligand [11C]-PBR28 Amyotrophic lateral sclerosis (ALS)
MedDRA version: 21.1;Level: PT;Classification code 10002026;Term: Amyotrophic lateral sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Product Code: BLZ945
INN or Proposed INN: Not yet defined
Other descriptive name: BLZ945
Product Code: BLZ945
INN or Proposed INN: Not yet defined
Other descriptive name: BLZ945		Novartis Pharma AGNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes		20Phase 2United States;Finland;Sweden
4EUCTR2019-000826-22-SE
(EUCTR)		17/09/201902/08/2019Study of safety and of the mechanism of BLZ945 in amyotrophic lateral sclerosis (ALS) patients.An open-label, adaptive design study in patients with amyotrophic lateral sclerosis (ALS) to characterize safety, tolerability and brain microglia response, as measured by TSPO binding, following multiple doses of BLZ945 using positron emission tomography (PET) with the radioligand [11C]-PBR28 Amyotrophic lateral sclerosis (ALS)
MedDRA version: 21.1;Level: PT;Classification code 10002026;Term: Amyotrophic lateral sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]		Product Code: BLZ945
INN or Proposed INN: Not yet defined
Other descriptive name: BLZ945
Product Code: BLZ945
INN or Proposed INN: Not yet defined
Other descriptive name: BLZ945		Novartis Pharma AGNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes		20Phase 2United States;Finland;Sweden
5NCT03520517
(ClinicalTrials.gov)		February 2, 201817/4/2018Open-label Study to Evaluate Safety, Tolerability and PK of BHV-0223 in ALSOpen-Label Study to Evaluate Safety, Tolerability and Pharmacokinetics of Multiple Doses of BHV-0223 in Subjects With Amyotrophic Lateral SclerosisAmyotrophic Lateral Sclerosis;ALS;Lou Gehrig Disease;Lou Gehrig's Disease;Lou-Gehrigs Disease;Motor Neuron Disease, Amyotrophic Lateral SclerosisDrug: BHV-0223Biohaven Pharmaceuticals, Inc.Cognitive Research CorporationCompleted18 YearsN/AAll22Phase 1United States
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
6NCT02870634
(ClinicalTrials.gov)		November 16, 201610/8/2016Phase 1 Dose Escalation and PK Study of Cu(II)ATSM in ALS/MNDA Phase 1 Single and Multiple Dose Escalation and Pharmacokinetic Study of Cu(II)ATSM Administered Orally to Patients With Amyotrophic Lateral Sclerosis/Motor Neuron DiseaseAmyotrophic Lateral Sclerosis;Motor Neuron DiseaseDrug: Cu(II)ATSMCollaborative Medicinal Development Pty LimitedNULLCompleted18 Years75 YearsAll50Phase 1Australia
7NCT01424163
(ClinicalTrials.gov)		August 201128/7/2011Dexpramipexole Japanese PK StudyA Single and Multiple Dose, Open-Label Study of the Pharmacokinetics, Safety, and Tolerability of Dexpramipexole (BIIB050) in Healthy Japanese and Caucasian SubjectsAmyotrophic Lateral SclerosisDrug: Single dose reduced;Drug: Single dose standard;Drug: Multiple DoseKnopp BiosciencesBiogen IdecCompleted18 Years60 YearsBoth56Phase 1United Kingdom
8NCT01378676
(ClinicalTrials.gov)		June 201120/6/2011A Study to Evaluate the Effects of Multiple Doses of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)A Phase II, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Effects of Multiple Doses of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)Amyotrophic Lateral SclerosisDrug: Placebo (Part A);Drug: CK-2017357 (Part A);Drug: Riluzole 50 MG (Part B);Drug: Placebo (Part B);Drug: CK-2017357 (Part B)CytokineticsNULLCompleted18 YearsN/AAll49Phase 2United States

Back to top